Skip to main content

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes


Anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) therapies represent a novel approach to cancer treatment via disruption of immune tolerance to antigens located on tumor cells. Disruption of immune tolerance, however, may occur at a cost. A host of immune related adverse events (IRAEs) are associated with anti-CTLA-4 therapy. Autoimmune hypophysitis has been reported in up to 17% of patients with melanoma and renal cell carcinoma treated with this therapy. Familiarity with the spectrum of IRAEs connected to these therapies is paramount for endocrinologists, oncologists and those involved in the care of these subjects. We review here key aspects of diagnosis and treatment of anti-CTLA-4 antibody therapy resultant IRAEs. We describe the first two cases of hypopituitarism in prostate cancer subjects undergoing experimental therapy with ipilimumab. The clinical evidence strongly suggests that the prostate cancer subjects developed autoimmune hypophysitis as a consequence of anti-CTLA-4 treatment. High dose glucocorticoid treatment resulted in markedly improved symptoms, and resolution of focal symptoms and diabetes insipidus. One subject recovered pituitary-thyroid axis function after 9 months; however, both continue to require GC replacement. These cases highlight the importance of early screening and treatment for hypopituitarism in all subjects undergoing treatment with anti-CTLA-4 therapy to prevent a potentially fatal outcome from secondary adrenal insufficiency, a readily treatable disease. We recommend mandatory long term follow-up to monitor the development of other hormonal deficits.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3


  1. 1.

    Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541–547

    Google Scholar 

  2. 2.

    Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985–988

    Google Scholar 

  3. 3.

    van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355–366

    Google Scholar 

  4. 4.

    Hurwitz AA, Yu TF, Leach DR, Allison JP (1998) CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 95:10067–10071

    Google Scholar 

  5. 5.

    Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60:2444–2448

    Google Scholar 

  6. 6.

    Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736

    Google Scholar 

  7. 7.

    Houot R, Levy R (2009) T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 113:3546–3552

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Jinushi M, Hodi FS, Dranoff G (2006) Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci 103:9190–9195

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Fala F, Fabbi M, Kato T, Lucarelli E, Donati D, Polito L, Bolognesi A, Ricci F, Salvi S, Gargaglione V, Mantero S, Alberghini M, Ferrara GB, Pistillo MP (2005) CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538–550

    Google Scholar 

  10. 10.

    Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043–6053

    Google Scholar 

  11. 11.

    Chung KY, Gore I, Fong L, Venook A, Dorazio P, Healey D, Pavlov D, Saltz LB (2007) A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675, 206,in patients with refractory metastatic adenocarcinoma of the colon or rectum. J Clin Oncol 25:3035 (Meeting Abstracts)

    Google Scholar 

  12. 12.

    Davis TA, Tchekmedyian S, Korman A, Keler T, Deo Y, Small EJ (2002) MDX-010 (human anti-CTLA4): a phase 1 trial in hormone refractory prostate carcinoma (HRPC). Proc Am Soc Clin Oncol 21:74

    Google Scholar 

  13. 13.

    Fischkoff SA, Hersh E, Weber J, Powderly J, Khan K, Pavlick A, Samlowski W, O’Day S, Nichol G, Yellin M (2005) Durable responses and progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. J Clin Oncol 23:7525 (Meeting Abstracts)

    Google Scholar 

  14. 14.

    Fong L, Kavanagh B, Rini BI, Shaw V, Weinberg V, Small EJ (2006) A phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer. J Clin Oncol 24:2508 (Meeting Abstracts)

    Google Scholar 

  15. 15.

    Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712–4717

    Google Scholar 

  16. 16.

    Morton DL, Mozzillo N, Thompson JF, Kelley MC, Faries M, Wagner J, Schneebaum S, Schuchter L, Gammon G, Elashoff R, Group MCT (2007) An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 25:8508 (Meeting Abstracts)

    Google Scholar 

  17. 17.

    Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372–8377

    Google Scholar 

  18. 18.

    Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J (2005) Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J Clin Oncol 23:8968–8977

    Google Scholar 

  19. 19.

    Thompson RH, Allison JP, Kwon ED (2006) Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol 24:442–447

    Google Scholar 

  20. 20.

    Weber JS, Targan S, Scotland R, Snively J, Garcia M, Yellin M, Fischkoff S, Nicho l (2006) Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma. J Clin Oncol 24: 2510 (Meeting Abstracts)

  21. 21.

    Yang JC, Beck KE, Blansfield JA, Tran KQ, Lowy I, Rosenberg SA (2005) Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). J Clin Oncol 23:2501 (Meeting Abstracts)

    Google Scholar 

  22. 22.

    Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM (2005) Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28:593–598

    Google Scholar 

  23. 23.

    Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681–6688

    Google Scholar 

  24. 24.

    Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF (2009) Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma Cancer. Immunol Immunother 58:1351–1353

    Google Scholar 

  25. 25.

    Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12:1005–1016

    Google Scholar 

  26. 26.

    Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA (2006) Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29:455–463

    Google Scholar 

  27. 27.

    Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP (2007) A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13:1810–1815

    Google Scholar 

  28. 28.

    Weber JS, O’Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E (2008) Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26:5950–5956

    Article  CAS  PubMed  Google Scholar 

  29. 29.

    Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30:825–830

    Google Scholar 

  30. 30.

    Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, Jooss K (2008) Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother 57:1263–1270

    Google Scholar 

  31. 31.

    Weber J (2007) Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12:864–872

    Google Scholar 

  32. 32.

    Caturegli P, Lupi I, Landek-Salgado M, Kimura H, Rose NR (2008) Pituitary autoimmunity: 30 years later Autoimmunity. Reviews 7:631–637

    Google Scholar 

  33. 33.

    Abe T (2008) Lymphocytic infundibulo-neurohypophysitis and infundibulo-panhypophysitis regarded as lymphocytic hypophysitis variant. Brain Tumor Pathol 25:59–66

    Article  PubMed  Google Scholar 

  34. 34.

    Abe T, Matsumoto K, Sanno N, Osamura Y (1995) Lymphocytic hypophysitis: case report. Neurosurgery 36:1016–1019

    Article  CAS  PubMed  Google Scholar 

  35. 35.

    Beressi N, Beressi JP, Cohen R, Modigliani E (1999) Lymphocytic hypophysitis. A review of 145 cases. Ann Med Interne (Paris) 150:327–341

    Google Scholar 

  36. 36.

    Laws ER, Vance ML, Jane JA Jr (2006) Hypophysitis. Pituitary 9:331–333

    Article  PubMed  Google Scholar 

  37. 37.

    Leung GK, Lopes MB, Thorner MO, Vance ML, Laws ER, Jr (2004) Primary hypophysitis: a single-center experience in 16 cases. J Neurosurg 101:262–271

    Google Scholar 

  38. 38.

    Rivera JA (2006) Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy. Pituitary 9:35–45

    Article  PubMed  Google Scholar 

  39. 39.

    Tubridy N, Saunders D, Thom M, Asa SL, Powell M, Plant GT, Howard R (2001) Infundibulohypophysitis in a man presenting with diabetes insipidus and cavernous sinus involvement. J Neurol Neurosurg Psychiatry 71:798–801

    Article  CAS  PubMed  Google Scholar 

  40. 40.

    McIntyre EA, Perros P (2007) Fatal inflammatory hypophysitis. Pituitary 10:107–111

    Article  PubMed  Google Scholar 

  41. 41.

    Ward L, Paquette J, Seidman E, Huot C, Alvarez F, Crock P, Delvin E, Kampe O, Deal C (1999) Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy. J Clin Endocrinol Metab 84:844–852

    Article  CAS  PubMed  Google Scholar 

Download references


The authors thank Shirley McCartney, Ph.D., for editorial assistance, and Andy Rekito, MS, for assistance with digital imaging.

Author information



Corresponding author

Correspondence to Maria Fleseriu.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Dillard, T., Yedinak, C.G., Alumkal, J. et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 13, 29–38 (2010).

Download citation


  • Lymphocytic hypophysitis
  • Autoimmune hypophysitis
  • Drug-induced hypophysitis
  • Hypopituitarism
  • Cytotoxic T-lymphocyte antigen-4
  • Prostate cancer
  • Immune related adverse events (IRAEs)